|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||1.2700 - 1.3200|
|52-week range||0.9900 - 3.0000|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Whilst it may not be a huge deal, we thought it was good to see that the OncoCyte Corporation (NYSEMKT:OCX) CEO...
OncoCyte (OCX) delivered earnings and revenue surprises of -27.27% and 257.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Celebrations may be in order for OncoCyte Corporation (NYSEMKT:OCX) shareholders, with the analysts delivering a...